Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug‐eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma

Aim Hepatocellular carcinoma (HCC) has a poor prognosis. Moreover, large HCCs have been commonly observed. We aimed to evaluate the efficacy and safety of drug‐eluting beads transarterial chemoembolization (DEB‐TACE) combined with conventional TACE (cTACE) for the treatment of patients with unresect...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology research 2021-04, Vol.51 (4), p.482-489
Main Authors: Chen, Shiguang, Yu, Wenchang, Zhang, Kongzhi, Liu, Weifu, Chen, Chuanben
Format: Article
Language:English
Subjects:
Adverse events
Constipation
drug‐eluting beads
Embolization
epirubicin
gelatin sponge particle
Hepatocellular carcinoma
Liver cancer
Nausea
Patients
Response rates
transarterial chemoembolization
Vomiting
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3810-154456aed9f52683ae1fef2b515d47aaf0734e37d8b4e46c1a6e0c57aaf8ab1a3
cites cdi_FETCH-LOGICAL-c3810-154456aed9f52683ae1fef2b515d47aaf0734e37d8b4e46c1a6e0c57aaf8ab1a3
container_end_page 489
container_issue 4
container_start_page 482
container_title Hepatology research
container_volume 51
creator Chen, Shiguang
Yu, Wenchang
Zhang, Kongzhi
Liu, Weifu
Chen, Chuanben
description Aim Hepatocellular carcinoma (HCC) has a poor prognosis. Moreover, large HCCs have been commonly observed. We aimed to evaluate the efficacy and safety of drug‐eluting beads transarterial chemoembolization (DEB‐TACE) combined with conventional TACE (cTACE) for the treatment of patients with unresectable large HCCs (main tumor ≥5 cm in diameter) compared with cTACE alone. Methods A retrospective matched cohort study was performed on consecutive patients with unresectable large HCCs who underwent TACE as the initial treatment at the Fujian Medical University Cancer Hospital from May 2017 and March 2019. Fifty‐five patients who underwent DEB‐TACE combined with cTACE were compared with a case‐matched control group of 110 patients who received cTACE alone. We compared the tumor response at 1 and 3 months after TACE, time to progression (TTP), and adverse events between the groups. Results The objective response rate was higher for the DEB‐TACE combined with cTACE group than for the cTACE alone group at 1 (39 of 55 [70.9%] vs. 57 of 110 [51.8%], p = 0.019) and 3 months (27 of 43 [62.8%] vs. 31 of 71 [43.7%], p = 0.048) post‐treatment. The DEB‐TACE combined with cTACE group also had a significantly longer median TTP than that of the cTACE group (7.2 vs. 5.3 months, p = 0.039). Compared with the cTACE group, occurrences of abdominal pain, nausea/vomiting, and constipation were significantly more frequent in the DEB‐TACE combined with cTACE group (p 
doi_str_mv 10.1111/hepr.13620
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2479043541</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2509221432</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3810-154456aed9f52683ae1fef2b515d47aaf0734e37d8b4e46c1a6e0c57aaf8ab1a3</originalsourceid><addsrcrecordid>eNp9kc2KFDEQx4Mo7rp68QEk4EWEXvPVH3OUYXWFBUUUvDXV6cpMlu5kzIfLePIRfC1fwycxPbMKejCXVKp-9a8kf0Iec3bOy3qxxV0457IR7A455V0rKibVp7slll1TNVI1J-RBjNeM8ZYJdZ-cyJITK1Gfkh9rP-8g2Ogd9YamLVI0xmrQewpupBEMpv1S0t59QZesdzDRFMBFCAmDLSe9xdnjPPjJfoWFoDc2bQ_9S-BzomPIm5_fvuOUk3UbOiCMkf7VYnw4jE8BIc1l0jI0u4ARdYJhQjpB2CAtr4XkNU5TLgmqIWjr_AwPyT0DU8RHt_sZ-fjq4sP6srp6-_rN-uVVpWXHWcVrpeoGcFyZWjSdBOQGjRhqXo-qBTCslQplO3aDQtVoDg0yXS-VDgYO8ow8O-rugv-cMaZ-tnG5Djj0OfZCtSumZK14QZ_-g177HMr_FapmKyG4kqJQz4-UDj7GgKbfBTtD2Pec9YvB_WJwfzC4wE9uJfMw4_gH_e1oAfgRuLET7v8j1V9evHt_FP0FmxG4RA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2509221432</pqid></control><display><type>article</type><title>Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug‐eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma</title><source>Wiley</source><creator>Chen, Shiguang ; Yu, Wenchang ; Zhang, Kongzhi ; Liu, Weifu ; Chen, Chuanben</creator><creatorcontrib>Chen, Shiguang ; Yu, Wenchang ; Zhang, Kongzhi ; Liu, Weifu ; Chen, Chuanben</creatorcontrib><description>Aim Hepatocellular carcinoma (HCC) has a poor prognosis. Moreover, large HCCs have been commonly observed. We aimed to evaluate the efficacy and safety of drug‐eluting beads transarterial chemoembolization (DEB‐TACE) combined with conventional TACE (cTACE) for the treatment of patients with unresectable large HCCs (main tumor ≥5 cm in diameter) compared with cTACE alone. Methods A retrospective matched cohort study was performed on consecutive patients with unresectable large HCCs who underwent TACE as the initial treatment at the Fujian Medical University Cancer Hospital from May 2017 and March 2019. Fifty‐five patients who underwent DEB‐TACE combined with cTACE were compared with a case‐matched control group of 110 patients who received cTACE alone. We compared the tumor response at 1 and 3 months after TACE, time to progression (TTP), and adverse events between the groups. Results The objective response rate was higher for the DEB‐TACE combined with cTACE group than for the cTACE alone group at 1 (39 of 55 [70.9%] vs. 57 of 110 [51.8%], p = 0.019) and 3 months (27 of 43 [62.8%] vs. 31 of 71 [43.7%], p = 0.048) post‐treatment. The DEB‐TACE combined with cTACE group also had a significantly longer median TTP than that of the cTACE group (7.2 vs. 5.3 months, p = 0.039). Compared with the cTACE group, occurrences of abdominal pain, nausea/vomiting, and constipation were significantly more frequent in the DEB‐TACE combined with cTACE group (p &lt; 0.05). Conclusion Compared with cTACE alone, DEB‐TACE combined with cTACE significantly increased the objective response rate at 1 and 3 months after the treatment of unresectable large HCCs, and had a longer TTP, without any significant increase in the number of severe complications.</description><identifier>ISSN: 1386-6346</identifier><identifier>EISSN: 1872-034X</identifier><identifier>DOI: 10.1111/hepr.13620</identifier><identifier>PMID: 33462925</identifier><language>eng</language><publisher>Netherlands: Wiley Subscription Services, Inc</publisher><subject>Adverse events ; Constipation ; drug‐eluting beads ; Embolization ; epirubicin ; gelatin sponge particle ; Hepatocellular carcinoma ; Liver cancer ; Nausea ; Patients ; Response rates ; transarterial chemoembolization ; Vomiting</subject><ispartof>Hepatology research, 2021-04, Vol.51 (4), p.482-489</ispartof><rights>2021 The Japan Society of Hepatology</rights><rights>2021 The Japan Society of Hepatology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3810-154456aed9f52683ae1fef2b515d47aaf0734e37d8b4e46c1a6e0c57aaf8ab1a3</citedby><cites>FETCH-LOGICAL-c3810-154456aed9f52683ae1fef2b515d47aaf0734e37d8b4e46c1a6e0c57aaf8ab1a3</cites><orcidid>0000-0002-9318-0383</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33462925$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Shiguang</creatorcontrib><creatorcontrib>Yu, Wenchang</creatorcontrib><creatorcontrib>Zhang, Kongzhi</creatorcontrib><creatorcontrib>Liu, Weifu</creatorcontrib><creatorcontrib>Chen, Chuanben</creatorcontrib><title>Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug‐eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma</title><title>Hepatology research</title><addtitle>Hepatol Res</addtitle><description>Aim Hepatocellular carcinoma (HCC) has a poor prognosis. Moreover, large HCCs have been commonly observed. We aimed to evaluate the efficacy and safety of drug‐eluting beads transarterial chemoembolization (DEB‐TACE) combined with conventional TACE (cTACE) for the treatment of patients with unresectable large HCCs (main tumor ≥5 cm in diameter) compared with cTACE alone. Methods A retrospective matched cohort study was performed on consecutive patients with unresectable large HCCs who underwent TACE as the initial treatment at the Fujian Medical University Cancer Hospital from May 2017 and March 2019. Fifty‐five patients who underwent DEB‐TACE combined with cTACE were compared with a case‐matched control group of 110 patients who received cTACE alone. We compared the tumor response at 1 and 3 months after TACE, time to progression (TTP), and adverse events between the groups. Results The objective response rate was higher for the DEB‐TACE combined with cTACE group than for the cTACE alone group at 1 (39 of 55 [70.9%] vs. 57 of 110 [51.8%], p = 0.019) and 3 months (27 of 43 [62.8%] vs. 31 of 71 [43.7%], p = 0.048) post‐treatment. The DEB‐TACE combined with cTACE group also had a significantly longer median TTP than that of the cTACE group (7.2 vs. 5.3 months, p = 0.039). Compared with the cTACE group, occurrences of abdominal pain, nausea/vomiting, and constipation were significantly more frequent in the DEB‐TACE combined with cTACE group (p &lt; 0.05). Conclusion Compared with cTACE alone, DEB‐TACE combined with cTACE significantly increased the objective response rate at 1 and 3 months after the treatment of unresectable large HCCs, and had a longer TTP, without any significant increase in the number of severe complications.</description><subject>Adverse events</subject><subject>Constipation</subject><subject>drug‐eluting beads</subject><subject>Embolization</subject><subject>epirubicin</subject><subject>gelatin sponge particle</subject><subject>Hepatocellular carcinoma</subject><subject>Liver cancer</subject><subject>Nausea</subject><subject>Patients</subject><subject>Response rates</subject><subject>transarterial chemoembolization</subject><subject>Vomiting</subject><issn>1386-6346</issn><issn>1872-034X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kc2KFDEQx4Mo7rp68QEk4EWEXvPVH3OUYXWFBUUUvDXV6cpMlu5kzIfLePIRfC1fwycxPbMKejCXVKp-9a8kf0Iec3bOy3qxxV0457IR7A455V0rKibVp7slll1TNVI1J-RBjNeM8ZYJdZ-cyJITK1Gfkh9rP-8g2Ogd9YamLVI0xmrQewpupBEMpv1S0t59QZesdzDRFMBFCAmDLSe9xdnjPPjJfoWFoDc2bQ_9S-BzomPIm5_fvuOUk3UbOiCMkf7VYnw4jE8BIc1l0jI0u4ARdYJhQjpB2CAtr4XkNU5TLgmqIWjr_AwPyT0DU8RHt_sZ-fjq4sP6srp6-_rN-uVVpWXHWcVrpeoGcFyZWjSdBOQGjRhqXo-qBTCslQplO3aDQtVoDg0yXS-VDgYO8ow8O-rugv-cMaZ-tnG5Djj0OfZCtSumZK14QZ_-g177HMr_FapmKyG4kqJQz4-UDj7GgKbfBTtD2Pec9YvB_WJwfzC4wE9uJfMw4_gH_e1oAfgRuLET7v8j1V9evHt_FP0FmxG4RA</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Chen, Shiguang</creator><creator>Yu, Wenchang</creator><creator>Zhang, Kongzhi</creator><creator>Liu, Weifu</creator><creator>Chen, Chuanben</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9318-0383</orcidid></search><sort><creationdate>202104</creationdate><title>Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug‐eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma</title><author>Chen, Shiguang ; Yu, Wenchang ; Zhang, Kongzhi ; Liu, Weifu ; Chen, Chuanben</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3810-154456aed9f52683ae1fef2b515d47aaf0734e37d8b4e46c1a6e0c57aaf8ab1a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adverse events</topic><topic>Constipation</topic><topic>drug‐eluting beads</topic><topic>Embolization</topic><topic>epirubicin</topic><topic>gelatin sponge particle</topic><topic>Hepatocellular carcinoma</topic><topic>Liver cancer</topic><topic>Nausea</topic><topic>Patients</topic><topic>Response rates</topic><topic>transarterial chemoembolization</topic><topic>Vomiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Shiguang</creatorcontrib><creatorcontrib>Yu, Wenchang</creatorcontrib><creatorcontrib>Zhang, Kongzhi</creatorcontrib><creatorcontrib>Liu, Weifu</creatorcontrib><creatorcontrib>Chen, Chuanben</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Shiguang</au><au>Yu, Wenchang</au><au>Zhang, Kongzhi</au><au>Liu, Weifu</au><au>Chen, Chuanben</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug‐eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma</atitle><jtitle>Hepatology research</jtitle><addtitle>Hepatol Res</addtitle><date>2021-04</date><risdate>2021</risdate><volume>51</volume><issue>4</issue><spage>482</spage><epage>489</epage><pages>482-489</pages><issn>1386-6346</issn><eissn>1872-034X</eissn><abstract>Aim Hepatocellular carcinoma (HCC) has a poor prognosis. Moreover, large HCCs have been commonly observed. We aimed to evaluate the efficacy and safety of drug‐eluting beads transarterial chemoembolization (DEB‐TACE) combined with conventional TACE (cTACE) for the treatment of patients with unresectable large HCCs (main tumor ≥5 cm in diameter) compared with cTACE alone. Methods A retrospective matched cohort study was performed on consecutive patients with unresectable large HCCs who underwent TACE as the initial treatment at the Fujian Medical University Cancer Hospital from May 2017 and March 2019. Fifty‐five patients who underwent DEB‐TACE combined with cTACE were compared with a case‐matched control group of 110 patients who received cTACE alone. We compared the tumor response at 1 and 3 months after TACE, time to progression (TTP), and adverse events between the groups. Results The objective response rate was higher for the DEB‐TACE combined with cTACE group than for the cTACE alone group at 1 (39 of 55 [70.9%] vs. 57 of 110 [51.8%], p = 0.019) and 3 months (27 of 43 [62.8%] vs. 31 of 71 [43.7%], p = 0.048) post‐treatment. The DEB‐TACE combined with cTACE group also had a significantly longer median TTP than that of the cTACE group (7.2 vs. 5.3 months, p = 0.039). Compared with the cTACE group, occurrences of abdominal pain, nausea/vomiting, and constipation were significantly more frequent in the DEB‐TACE combined with cTACE group (p &lt; 0.05). Conclusion Compared with cTACE alone, DEB‐TACE combined with cTACE significantly increased the objective response rate at 1 and 3 months after the treatment of unresectable large HCCs, and had a longer TTP, without any significant increase in the number of severe complications.</abstract><cop>Netherlands</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33462925</pmid><doi>10.1111/hepr.13620</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-9318-0383</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1386-6346
ispartof Hepatology research, 2021-04, Vol.51 (4), p.482-489
issn 1386-6346
1872-034X
language eng
recordid cdi_proquest_miscellaneous_2479043541
source Wiley
subjects Adverse events
Constipation
drug‐eluting beads
Embolization
epirubicin
gelatin sponge particle
Hepatocellular carcinoma
Liver cancer
Nausea
Patients
Response rates
transarterial chemoembolization
Vomiting
title Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug‐eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T00%3A21%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20the%20efficacy%20and%20safety%20of%20conventional%20transarterial%20chemoembolization%20with%20and%20without%20drug%E2%80%90eluting%20beads%20embolization%20for%20the%20treatment%20of%20unresectable%20large%20hepatocellular%20carcinoma&rft.jtitle=Hepatology%20research&rft.au=Chen,%20Shiguang&rft.date=2021-04&rft.volume=51&rft.issue=4&rft.spage=482&rft.epage=489&rft.pages=482-489&rft.issn=1386-6346&rft.eissn=1872-034X&rft_id=info:doi/10.1111/hepr.13620&rft_dat=%3Cproquest_cross%3E2509221432%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3810-154456aed9f52683ae1fef2b515d47aaf0734e37d8b4e46c1a6e0c57aaf8ab1a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2509221432&rft_id=info:pmid/33462925&rfr_iscdi=true